Compare Bristol-Myers Squibb Co (BMY) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Bank of Nova Scotia — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Bank of Nova Scotia trades at $89.87 (market cap $108.32B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | BNS | |
|---|---|---|
Market Cap | $129.94B | $108.32B |
Sector | Health | Financials |
52-Week High | $65.89 | $90.29 |
52-Week Low | $42.60 | $56.41 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Bank of Nova Scotia (BNS) trades at $88.56, down 0.33% on the day. The stock exhibits a bullish technical trend with strong analyst support, evidenced by a 'Buy' consensus from 53% of covering analysts. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.47 surpassing the $1.42 estimate. The company maintains a solid net income margin of 24.86% and recently announced a dividend of $1.14 per share, highlighting its commitment to shareholder returns.
The outlook for BNS is positive, supported by earnings momentum, a diversified banking model, and an attractive dividend. Key risks include exposure to macroeconomic volatility and competitive pressures in the banking sector. The current valuation, with a P/E of 17.1, appears reasonable relative to its profitability and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
